Back to Careers

Tina Duong PT, PHD

linkedin-icon-green


Tina Duong is the Director of clinical outcomes research and development at Stanford University Neuromuscular division. Clinically, she is a physical therapist with 20 years of clinical experience in evaluating, treating and validating clinical outcomes for patients with neuromuscular disease. 

Her clinical and research interests are in developing, refining and understanding impacts of muscle imbalances and pathology on function and performance. Her work has contributed to improved understanding and characterization of disease phenotypes impacting clinical trial design and care management.

Currently, her research focuses on the effect of exercise and physical activity on human movement and disease physiology. She hopes to integrate technology and digital biomarkers as a complementary tool to performance based measures used in trials, in the clinic and remotely. She enjoys working on collaborative diverse inter-disciplinary teams, mentorship and creating patient focused solutions to improve the quality of life for individuals with neuromuscular disease.

Learn more about Tina

LinkedIn

Back to Careers

John W. Day, MD, PhD

linkedin-icon-green

Since 2011 John has been Professor of Neurology, Pediatrics (Genetics) and Pathology at Stanford University, where he is Director of the Division of Neuromuscular Medicine. He received his MD from the University of Minnesota, and PhD in Neuroscience from Albert Einstein College of Medicine, where he studied neuronal electrophysiology, synaptic physiology and plasticity.  After completing neurology and neuromuscular training at UCSF, he was Professor of Neurology, Pediatrics and Genetics at the University of Minnesota, where he founded and directed the Paul and Sheila Wellstone Muscular Dystrophy Center. 

John has investigated the genetic causes and multisystemic effects of neuromuscular disorders and has more than 35 years of experience designing and directing clinical trials of novel therapeutics.  He spearheaded clinical research on spinal muscular atrophy (SMA) at Stanford, which resulted in the approval of antisense and AAV-gene replacement treatments, and led to nationwide newborn screening for SMA and institution of neonatal genetic treatment.

Learn more about John

LinkedIn

Back to Careers

Shari-Anne Burgess, RN

linkedin-icon-green

Shari Burgess brings over 25 years of clinical experience to the life science and healthcare industry working in a variety of indications such as but not limited to oncology, neuromuscular disorders, rare disease, regenerative medicine, burn and wound care and orthopedics. She is the Chief Clinical Operations Lead in her clinical consulting company, Clinsytes Inc., a  niche clinical consulting company that provides global  clinical operation insights and solutions for small to midsize life science companies for the improvement of clinical operational performance and delivery of measurables in drug/device development, trial management and business development strategies. Previous to Clinsytes, Shari held senior management roles at CROs and medical/biotech companies.

Learn more about Shari-Anne

LinkedIn

Back to Careers

To help drive change in biotech, Dr. Hanadie Yousef joined the industry’s leading women CEOs and investors at  the first joint Women Investors and CEOs networking event hosted by Sofinnova Investments and Cowen. Together these women are driven to create positive change in the industry, improving diversity among biotech c-suite and investors and supporting one another.

Back to Careers

Austin Wang, PhD

linkedin-icon-green

Dr. Austin Wang joined Juvena Therapeutics as a Corporate Development Manager. Before joining, Dr. Wang spent 6 months as a Neuroscience Fellow at Mubadala Capital and also conducted several consulting engagements as a part of Biotech Connections Bay Area with biotech and venture capital firms. Dr. Wang comes with experience in clinical trial assessments, asset evaluation, and market/competitive landscape.

Dr. Wang received his PhD in Neuroscience from UCSF in Dr. Aimee Kao’s lab where he studied the cellular molecular properties of neurodegeneration, with an emphasis on protein homeostasis through lysosomal regulation. Prior to UCSF, he spent two years studying the biochemical regulation of neuronal vesicle fusion in Dr. Axel Brunger’s lab at Stanford University. He graduated from UCLA with a B.S. in Physiological Science where he studied neuronal pathways underlying sensory integration in Dr. Mark Frye’s lab. In addition to his first-author publication in Human Molecular Genetics, Dr. Wang has co-authored 9 publications in top-tier journals, including a second author Nature paper.

Dr. Wang is passionate about translating scientific research into commercially successful clinical solutions for patients. At Juvena Therapeutics, he works in a cross functional capacity to support many functions related to corporate development. Outside of work, he enjoys cycling on the weekends and playing strategy board games.

Learn more about Austin

LinkedIn

Back to Careers

Mingyu Chung, PhD

linkedin-icon-green

Min received his B.S. in Electrical Engineering at the University of Michigan and worked for five years as a product engineer at Samsung Austin Semiconductor. He received his Ph.D. in Chemical and Systems Biology at Stanford University, where he researched growth factor and cell cycle signaling in the laboratory of Tobias Meyer. He completed his postdoctoral training at Stanford University (laboratory of Thomas Rando), where he leveraged single-cell genomics and chemical and genetic screening to investigate the mechanisms of skeletal muscle stem cell fate specification. Min received an NIH F32 postdoctoral fellowship and is a co-author on 17 publications.

Learn more about Min
LinkedIn

Back to Careers

Trang Vuong

linkedin-icon-green

Trang joined Juvena Therapeutics as a Scientist to contribute to Dr. Li’s research on developing various assays for advancing Juvena Therapeutics’ pipeline library of rejuvenating proteins for therapeutic purposes. 

Trang obtained her undergraduate degree in Biochemistry and Molecular Biology from UC Davis and continued to study for her Master in Immunology at UC Davis. Before joining Juvena, she worked at Teva Pharmaceuticals and worked extensively in their antibody screening. She managed an early antibody discovery project and had experiences in running various animal models for lead efficacy testing. She has extensive experience in flow cytometry, assay development and project leadership.

Learn more about Trang

LinkedIn

Back to Careers

EARD 2022: Mapping Secreted Proteins to Unmet Medical Needs by Dr. Thach Mai at Juvena August 2022

Back to Careers

CEO Hanadie Yousef was honored to represent Juvena Therapeutics at BIO International Convention in June 2022, where she gave a Company Presentation at the emerging company showcase. She had numerous meetings with exciting companies and investors focused on partnerships and was all around inspired by the exceptional attendees, sponsors, and organizers. Thanks to The National Institutes of Health for sponsoring the Innovation Zone and Juvena’s attendance

Back to Careers

Wei (Vivian) Guo

Wei (Vivian) Guo brings over 20 years of biopharmaceutical industry experience focused on protein chemistry and therapeutic antibody development to her role as Senior Scientist of Protein Science at Juvena Therapeutics. 

She has broad and deep experience in protein and antibody expression, purification, and analytical characterization. She is also an expert in antibody generation including antigen design, protein conjugation, bispecific antibody generation and drug conjugation. She has extensive cross functional experience in molecular biology, cell culture and assay development, as well as deep trouble-shoot skills.

She received her medical college degree from Hunan Medical University in China.

Vivian loves nature, like walking, hiking, traveling and ping-pong.

Learn more about Vivian